CA1289075C - Produit pharmaceutique - Google Patents

Produit pharmaceutique

Info

Publication number
CA1289075C
CA1289075C CA000523051A CA523051A CA1289075C CA 1289075 C CA1289075 C CA 1289075C CA 000523051 A CA000523051 A CA 000523051A CA 523051 A CA523051 A CA 523051A CA 1289075 C CA1289075 C CA 1289075C
Authority
CA
Canada
Prior art keywords
composition
weight
ethyl cellulose
wax
fatty acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA000523051A
Other languages
English (en)
Inventor
Navnit H. Shah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25175361&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA1289075(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of CA1289075C publication Critical patent/CA1289075C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
CA000523051A 1985-11-18 1986-11-14 Produit pharmaceutique Expired - Lifetime CA1289075C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/799,229 US4892742A (en) 1985-11-18 1985-11-18 Controlled release compositions with zero order release
US799,229 1985-11-18

Publications (1)

Publication Number Publication Date
CA1289075C true CA1289075C (fr) 1991-09-17

Family

ID=25175361

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000523051A Expired - Lifetime CA1289075C (fr) 1985-11-18 1986-11-14 Produit pharmaceutique

Country Status (16)

Country Link
US (1) US4892742A (fr)
EP (1) EP0224146B1 (fr)
JP (1) JPS62120316A (fr)
CN (1) CN86107734A (fr)
AU (1) AU594392B2 (fr)
CA (1) CA1289075C (fr)
DE (1) DE3685094D1 (fr)
DK (1) DK546886A (fr)
GR (1) GR862727B (fr)
HU (1) HU200683B (fr)
IL (1) IL80643A0 (fr)
MC (1) MC1782A1 (fr)
NZ (1) NZ218297A (fr)
PH (1) PH23292A (fr)
PT (1) PT83756B (fr)
ZA (1) ZA868249B (fr)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2585246A1 (fr) * 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
SE8505034D0 (sv) * 1985-10-25 1985-10-25 Haessle Ab Kropp bestaende av en kerna med ett overdrag
EP0325086A3 (fr) * 1987-11-23 1990-10-31 Jago Research Ag Méthodes pour obtenir des systèmes thérapeutiques à libération contrôlée du médicament
IE60383B1 (en) * 1988-05-27 1994-07-13 Elan Corp Plc Controlled release pharmaceutical formulation
GB8813064D0 (en) * 1988-06-02 1988-07-06 Euro Celtique Sa Controlled release dosage forms having defined water content
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IT1237904B (it) * 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
US5876752A (en) * 1990-08-07 1999-03-02 Pfizer Inc. Use of interfacially-polymerized membranes in delivery devices
EP0546593B1 (fr) * 1991-10-30 1997-09-03 Glaxo Group Limited Compositions multicouches contenant d'antagonistes de l'histamine ou de la sérotonine
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5160742A (en) * 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
US5656296A (en) * 1992-04-29 1997-08-12 Warner-Lambert Company Dual control sustained release drug delivery systems and methods for preparing same
GB9325445D0 (en) 1993-12-13 1994-02-16 Cortecs Ltd Pharmaceutical formulations
US6787156B1 (en) * 1994-02-23 2004-09-07 Bm Research A/S Controlled release composition
US5458887A (en) * 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US5482718A (en) * 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
JPH08143450A (ja) * 1994-11-14 1996-06-04 Taiyo Yakuhin Kogyo Kk 徐放化製剤
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
FR2766708B1 (fr) * 1997-07-30 2000-05-05 Galenix Dev Composition contenant de l'hydroxypropylcellulose, de l'hydroxypropylmethylcellulose et/ou de l'ethylcellullose a titre d'agents desintegrants, et procede d'obtention
FR2766707A1 (fr) * 1997-07-30 1999-02-05 Galenix Dev Composition contenant de l'hydroxypropylcellulose, de l'hydroxypropylmethyl-cellulose et/ou de l'ethylcellulose a titre d'agents desintegrants, et procede d'obtention
US6607751B1 (en) * 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
DE69917618T2 (de) * 1998-04-03 2005-06-23 Egalet A/S Zusammensetzung mit kontrollierter wirkstoff-freisetzung
US20090297597A1 (en) * 1998-11-02 2009-12-03 Gary Liversidge Modified Release Ticlopidine Compositions
US20070122481A1 (en) * 1998-11-02 2007-05-31 Elan Corporation Plc Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
NZ511442A (en) * 1998-11-02 2003-02-28 Elan Corp Plc Multiparticulate modified release composition for multiple dosing of ADD patients with methylphenidate HCl
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
KR20020059653A (ko) 1999-10-29 2002-07-13 그린 마틴, 브라이언 쥐 테슬리 서방성 하이드로코돈 제형
EP1251832B1 (fr) 2000-02-04 2006-09-27 Depomed, Inc. Forme posologique enveloppe et noyau approchant la liberation d'ordre zero du medicament
EP1337244A4 (fr) 2000-10-30 2006-01-11 Euro Celtique Sa Preparations d'hydrocodone a liberation lente
US20030070584A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
AU4061702A (en) * 2001-05-15 2003-04-03 Mcneil-Ppc, Inc. Dip coating compositions containing starch or dextrin
WO2003024430A1 (fr) * 2001-09-21 2003-03-27 Egalet A/S Systeme a liberation de polymere de morphine
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
US8309118B2 (en) * 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
US7300668B2 (en) * 2001-10-29 2007-11-27 Massachusetts Institute Of Technology System for manufacturing controlled release dosage forms, such as a zero-order release profile dosage form manufactured by three-dimensional printing
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US20050163846A1 (en) * 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
US20030118647A1 (en) * 2001-12-04 2003-06-26 Pawan Seth Extended release tablet of metformin
MXPA04006163A (es) * 2001-12-20 2004-11-01 Pharmacia Corp Formas de dosis de liberacion sostenida del orden-cero y metodo de fabricacion de las mismas.
PT1485078E (pt) * 2002-03-15 2013-01-14 Cypress Bioscience Inc Milnacipran para o tratamento do síndrome do intestino irritável
US7429619B2 (en) * 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
CA2501324A1 (fr) * 2002-10-30 2004-05-21 Pharmacia Corporation Comprimes oraux a liberation etendue et procedes de fabrication et d'utilisation associes
EP1562552A1 (fr) * 2002-11-08 2005-08-17 Egalet A/S Compositions de carvedilol a liberation commandee
EP1592453A1 (fr) * 2003-01-28 2005-11-09 Collegium Pharmaceutical, Inc. Compositions multiparticulaires de milnacipran destinees a etre administrees par voie orale
ES2360102T3 (es) * 2003-03-26 2011-05-31 Egalet A/S Sistema para la liberación controlada de morfina.
EP1974726B1 (fr) * 2003-03-26 2010-01-13 Egalet A/S Compositions matricielles pour administration contrôlée de substances médicamenteuses
US8802139B2 (en) * 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US20080095839A1 (en) * 2004-03-26 2008-04-24 Eisai R&D Management Co., Ltd. Controlled-Release Pharmaceutical Composition and Method for Producing the Same
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060024361A1 (en) * 2004-07-28 2006-02-02 Isa Odidi Disintegrant assisted controlled release technology
US10624858B2 (en) * 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
CN100548309C (zh) * 2004-11-24 2009-10-14 东北制药总厂 司他夫定缓释片剂
US20060121112A1 (en) * 2004-12-08 2006-06-08 Elan Corporation, Plc Topiramate pharmaceutical composition
US8481565B2 (en) * 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
US7829000B2 (en) * 2005-02-25 2010-11-09 Hewlett-Packard Development Company, L.P. Core-shell solid freeform fabrication
CA2602268A1 (fr) * 2005-04-12 2006-10-19 Elan Pharma International Limited Compositions a liberation controlee comportant une celphalosporine pour le traitement d'une infection bacterienne
EP1895989A2 (fr) * 2005-06-03 2008-03-12 Egalet A/S Systeme d'apport de medicaments destine a apporter des substances actives dispersees dans un milieu de dispersion
US20100136106A1 (en) * 2005-06-08 2010-06-03 Gary Liversidge Modified Release Famciclovir Compositions
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20090148519A1 (en) * 2005-09-29 2009-06-11 Yasuhiro Zaima Pulsed-release preparation having improved disintegration properties in vivo
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CN104825397A (zh) * 2006-04-03 2015-08-12 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
US20100105738A1 (en) * 2006-10-06 2010-04-29 Mitsuru Mizuno Extended release formulations of a proton pump inhibitor
EP2104493A2 (fr) * 2007-01-16 2009-09-30 Egalet A/S Utilisation (i) d'un polyglycol et (ii) d'une substance médicamenteuse active dans la préparation d'une composition pharmaceutique destinée (i) à réduire le risque de libération massive induite par l'alcool et/ou (ii) à réduire le risque de toxicomanie médicamenteuse
WO2008148798A2 (fr) 2007-06-04 2008-12-11 Egalet A/S Compositions pharmaceutiques à libération contrôlée pour un effet prolongé
EP2214635A1 (fr) * 2007-10-19 2010-08-11 Purdue Research Foundation Formulations solides de composés cristallins
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
WO2010143202A1 (fr) * 2009-06-09 2010-12-16 Sun Pharmaceutical Industries Ltd. Composition pharmaceutique
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations
BR112015000150A2 (pt) 2012-07-06 2017-06-27 Egalet Ltd composições farmacêuticas dissuasoras de abuso de liberação controlada
CA2936746C (fr) 2014-10-31 2017-06-27 Purdue Pharma Methodes et compositions destinees au traitement du trouble de deficit d'attention
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1290661A (fr) * 1960-05-31 1962-04-13 Abbott Lab Méthode d'enrobage de comprimés
US4140756A (en) * 1976-06-10 1979-02-20 Mead Johnson & Company Film-coated matrix core tablet
DD146547A5 (de) * 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
US4309406A (en) * 1979-07-10 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4252786A (en) * 1979-11-16 1981-02-24 E. R. Squibb & Sons, Inc. Controlled release tablet
FR2506157A1 (fr) * 1981-05-20 1982-11-26 Lipha Preparation pharmaceutique de " naftidrofuryl " a liberation controlee
HU187215B (en) * 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
BR8406921A (pt) * 1983-05-31 1985-06-04 Choong Gook Jang Composicoes secas de compressao,direta para formas de dosagem de liberacao controlada
DE3413608A1 (de) * 1984-04-11 1985-10-24 Hoechst Ag, 6230 Frankfurt Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung
GB8521494D0 (en) * 1985-08-29 1985-10-02 Zyma Sa Controlled release tablet

Also Published As

Publication number Publication date
PH23292A (en) 1989-06-30
EP0224146A2 (fr) 1987-06-03
MC1782A1 (fr) 1987-09-02
CN86107734A (zh) 1987-05-20
ZA868249B (en) 1987-06-24
HU200683B (en) 1990-08-28
PT83756A (en) 1986-12-01
HUT42321A (en) 1987-07-28
IL80643A0 (en) 1987-02-27
DE3685094D1 (de) 1992-06-04
DK546886A (da) 1987-05-19
AU6532586A (en) 1987-05-21
DK546886D0 (da) 1986-11-14
AU594392B2 (en) 1990-03-08
PT83756B (pt) 1989-06-30
GR862727B (en) 1987-03-19
EP0224146B1 (fr) 1992-04-29
US4892742A (en) 1990-01-09
NZ218297A (en) 1990-03-27
EP0224146A3 (en) 1987-09-23
JPS62120316A (ja) 1987-06-01

Similar Documents

Publication Publication Date Title
CA1289075C (fr) Produit pharmaceutique
US7410652B2 (en) Controlled release and taste masking oral pharmaceutical composition
CA1265449A (fr) Dispositifs a debitage temporise de substances actives, et preparation desdits dispositifs
KR100712356B1 (ko) 서방성 제제 및 그의 제조방법
US4705695A (en) Method for coating pharmaceutical formulations
RU2127587C1 (ru) Устойчивые лекарственные формы с регулируемым выделением, имеющие акриловые полимерные покрытия, (варианты) и способ их получения
US4792452A (en) Controlled release formulation
FI121620B (fi) Menetelmiä aktiivisen aineen kontrolloidusti vapautuvan formulaation saamiseksi
US5149542A (en) Coating membrane and compositions prepared therefrom
FI91482B (fi) Menetelmä hitaasti vapauttavan kiinteän annostusmuodon valmistamiseksi
US4433076A (en) Coating agent for medicaments and methods for making and using the same
US5186943A (en) Compressed-molded preparations
EP0548448A1 (fr) Substrat stabilisé à libération contrôlée ayant une couche dérivée d'un dispersion aqueuse de polymère hydrophobe
IE83354B1 (en) Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
KR900005795B1 (ko) 피복 고형 제제의 제조방법
IE900862L (en) A drug-release controlling coating material for long acting¹formulations
GB1593062A (en) Coatings
EP0365947A1 (fr) Forme de dosage
EP0441245B1 (fr) Procédé de préparation de comprimés médicamenteux à libération retardée
US3275518A (en) Tablet coating
KR102543236B1 (ko) 벤토나이트를 포함하는 필름 코팅용 조성물
WO2005117839A1 (fr) Preparation de comprimes de paroxetine hydrochloride (hci) au moyen d'un procede de granulation par fusion
JP2017507164A (ja) 放出制御組成物及び方法
HK1005686B (en) Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer

Legal Events

Date Code Title Description
MKLA Lapsed